Development of an Abuse- and Alcohol-Resistant Formulation Based on Hot-Melt Extrusion and Film Coating

AAPS PharmSciTech

Volumn 17, Issue 1, 2016, Pages 68-77

  Jedinger, Nicole ^a   Schrank, Simone ^b   Fischer, Johannes M ^a   Breinhälter, Karlheinz ^a   Khinast, Johannes ^a,c   Roblegg, Eva ^a,b  

^a RESEARCH CENTER PHARMACEUTICAL ENGINEERING GMBH   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

dose dumping; drug tampering; melt extrusion; starch

Indexed keywords

ALCOHOL; CODEINE PHOSPHATE; ETHYL CELLULOSE; GUM ARABIC; PHENAZONE; STARCH; XANTHAN; BACTERIAL POLYSACCHARIDE; CELLULOSE; DELAYED RELEASE FORMULATION; DRUG; EXCIPIENT; POWDER;

ALCOHOL INDUCED DOSE DUMPING; AQUEOUS SOLUTION; ARTICLE; COMPRESSION STRENGTH; CRYSTALLIZATION; DEFORMABLE PELLET; DIELECTRIC CONSTANT; DRUG ABUSE; DRUG FORMULATION; DRUG METABOLISM; DRUG PELLET; DRUG RELEASE; DRUG SOLUBILITY; FILM COATING; HOT MELT EXTRUSION; PELLET EXTRUSION; PRIORITY JOURNAL; THERMOGRAPHY; WATER CONTENT; WATER LOSS; ANALOGS AND DERIVATIVES; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG STABILITY; HEAT; MEDICINAL CHEMISTRY; POWDER; PROCEDURES; SOLUBILITY;

CELLULOSE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG LIBERATION; DRUG STABILITY; ETHANOL; EXCIPIENTS; GUM ARABIC; HOT TEMPERATURE; PHARMACEUTICAL PREPARATIONS; POLYSACCHARIDES, BACTERIAL; POWDERS; SOLUBILITY; STARCH;

EID: 84959131580     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-015-0373-2     Document Type: Article

References (48)

1. Mastropietro DJ, Omidian H. Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev Ind Pharm. 2013;39(5):1–14.
2. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10(1):11–8.
3. Gourlay GK. Sustained relief of chronic pain: pharmacokinetics of sustained release morphine. Clin Pharmacokinet. 1998;35(3):173–90.
4. Skelly JP, Amidon GL, Barr WH, Benet LZ, Carter JE, Robinson JR, et al. In vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms. Pharm Res. 1990;7(9):975–82.
5. Walden M, Nicholls FA, Smith KJ, Tucker GT. The effect of ethanol on the release of opioids from oral prolonged-release preparations. Drug Dev Ind Pharm. 2007;33(10):1101–11.
6. Webster LR. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med. 2009;10(S2):S124–S33.
7. Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs. 2009;18(3):255–63.
8. FDA guidance for industry abuse-deterrent opioids—evaluation and labeling 2015 [11 Jun 2015]. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf.
9. Herry C, Monti A, Vauzelle-Kervroedan F, Oury P, Michel L. Reducing abuse of orally administered prescription opioids using formulation technologies. J Drug Deliv Sci Tech. 2013;23(2):103–10.
10. FDA approves abuse-deterrent labeling for reformulated OxyContin [12 Feb 2015]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htm.
11. FDA approves Targiniq ER with abuse-deterrent properties [12 Feb 2015]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm406290.htm.
12. FDA approves labeling with abuse-deterrent features for third extended-release opioid analgesic [12 Feb 2015]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm419288.htm.
13. TM ER (hydrocodone bitartrate) extended-release tablets CII, a once-daily opioid analgesic formulated with abuse-deterrent properties [04 Feb 2015]. Available from: http://www.purduepharma.com/news-media/2014/11/purdue-pharma-l-p-receives-fda-approval-for-hysinglatm-er-hydrocodone-bitartrate-extended-release-tablets-cii-a-once-daily-opioid-analgesic-formulated-with-abuse-deterrent-properties/.
14. TM ER (hydrocodone bitartrate) extended-release capsules [04 Feb 2015]. Available from: http://ir.zogenix.com/phoenix.zhtml?c=220862&p=irol-newsArticle&ID=1868848.
15. Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Benedek IH, Comer SD. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012;126(1–2):206–15.
16. Sokolowska M. FDA meeting on ADF—development and evaluation of abuse deterrent opioid formulations, part 1 2014 [12 Feb 2015]. Available from: http://www.fda.gov/downloads/Drugs/NewsEvents/UCM422383.pdf.
17. Jedinger N, Khinast J, Roblegg E. The design of controlled-release formulations resistant to alcohol-induced dose dumping—a review. Eur J Pharm Biopharm. 2014;87(2):217–26.
18. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94(7):961–72.
19. Wening K, Barnscheid L, Schwier S, Geißler A, inventors; Grünenthal GmbH, assignee. Tamper-resistant dosage form containing ethylene-vinyl acetate polymer patent. US 2015/0017250 A1. 2015.
20. Bartholomaeus JH, Ashworth JB, Stahlberg H-J, Galia E, Strothmann K. Innovative formulation technology protecting intended drug action. Drug Dev Deliv. 2012;12(8):76–81.
21. Khinast J, Baumgartner R, Roblegg E. Nano-extrusion: a one-step process for manufacturing of solid nanoparticle formulations directly from the liquid phase. AAPS PharmSciTech. 2013;14(2):601–4.
22. Baumgartner R, Eitzlmayr A, Matsko N, Tetyczka C, Khinast J, Roblegg E. Nano-extrusion: a promising tool for continuous manufacturing of solid nano-formulations. Int J Pharm. 2014;477:1–11.
23. Treffer D, Wahl PR, Hörmann TR, Markl D, Schrank S, Jones I, et al. In-line implementation of an image-based particle size measurement tool to monitor hot-melt extruded pellets. Int J Pharm. 2014;466(1–2):181–9.
24. Bialleck S, Rein H. Preparation of starch-based pellets by hot-melt extrusion. Eur J Pharm Biopharm. 2011;79(2):440–8.
25. Rosiaux Y, Muschert S, Chokshi R, Leclercq B, Siepmann F, Siepmann J. Ethanol-resistant polymeric film coatings for controlled drug delivery. J Control Release. 2013;169(1–2):1–9.
26. Rosiaux Y, Velghe C, Muschert S, Chokshi R, Leclercq B, Siepmann F, et al. Ethanol-resistant ethylcellulose/guar gum coatings—importance of formulation parameters. Eur J Pharm Biopharm. 2013;85((3, Part B)):1250–8.
27. Rosiaux Y, Velghe C, Muschert S, Chokshi R, Leclercq B, Siepmann F, et al. Mechanisms controlling theophylline release from ethanol-resistant coated pellets. Pharm Res. 2014;31(3):731–41.
28. Shipway PH, Hutchings IM. Fracture of brittle spheres under compression and impact loading. I. Elastic stress distributions. Philos Mag A. 1993;67(6):1389–404.
29. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Techno. 1996;20:64–74.
30. Paruta AN. Solubility profiles for antipyrine and aminopyrine in hydroalcoholic solutions. J Pharm Sci. 1967;56(12):1565–9.
31. Jedinger N, Schrank S, Mohr S, Feichtinger A, Khinast J, Roblegg E. Alcohol dose dumping: the influence of ethanol on hot-melt extruded pellets comprising solid lipids. Eur J Pharm Biopharm. 2015;92:83–95.
32. Li A, Yalkowsky SH. Solubility of organic solutes in ethanol/water mixtures. J Pharm Sci. 1994;83(12):1735–40.
33. Seedher N, Bhatia S. Solubility enhancement of cox-2 inhibitors using various solvent systems. AAPS PharmSciTech. 2003;4(3):36–44.
34. Yu F, Prashantha K, Soulestin J, Lacrampe M-F, Krawczak P. Plasticized-starch/poly (ethylene oxide) blends prepared by extrusion. Carbohyd Polym. 2013;91(1):253–61.
35. Liu H, Xie F, Yu L, Chen L, Li L. Thermal processing of starch-based polymers. Prog Polym Sci. 2009;34(12):1348–68.
36. Zohuriaan MJ, Shokrolahi F. Thermal studies on natural and modified gums. Polym Test. 2004;23(5):575–9.
37. Kipping T, Trindade R, Rein H. The use of hot-melt extruded corn starch matrices as drug carrier systems: a thermophysical characterization. Starch - Stärke. 2014;66(9–10):923–33.
38. Liu P, Yu L, Liu H, Chen L, Li L. Glass transition temperature of starch studied by a high-speed DSC. Carbohyd Polym. 2009;77(2):250–3.
39. Bialleck S. Herstellung von Polysaccharidpellets mittels Schmelzextrusion Bonn: Rheinische Friedrich-Wilhelms-Universität 2011. Available from: http://hss.ulb.uni-bonn.de/2012/2743/2743.htm.
40. Liu H, Yu L, Xie F, Chen L. Gelatinization of cornstarch with different amylose/amylopectin content. Carbohyd Polym. 2006;65(3):357–63.
41. Mothé CG, Rao MA. Thermal behavior of gum arabic in comparison with cashew gum. Thermochim Acta. 2000;357–358:9–13.
42. Wauer GF, Rein H. Solid solutions of tramadol-HCl based on starch. Pharm Ind. 2010;72:1973–9.
43. Petruševski G, Ugarkovic S, Makreski P. Solid-state transformation of the pseudopolymorphic forms of codeine phosphate hemihydrate and codeine phosphate sesquihydrate monitored by vibrational spectroscopy and thermal analysis. J Mol Struct. 2011;993(1–3):328–35.
44. Toti US, Soppimath KS, Mallikarjuna NN, Aminabhavi TM. Acrylamide-grafted-acacia gum polymer matrix tablets as erosion-controlled drug delivery systems. J Appl Polym Sci. 2004;93(5):2245–53.
45. Talukdar MM, Kinget R. Swelling and drug release behaviour of xanthan gum matrix tablets. Int J Pharm. 1995;120(1):63–72.
46. Vendruscolo CW, Andreazza IF, Ganter JLMS, Ferrero C, Bresolin TMB. Xanthan and galactomannan (from M. scabrella) matrix tablets for oral controlled delivery of theophylline. Int J Pharm. 2005;296(1–2):1–11.
47. FMC. BioPolymer Aquacoat® ARC [27 May 2013]. Available from: http://www.fmcbiopolymer.com/Pharmaceutical/Products/NEWAquacoatARC.aspx.
48. Bialleck S, Rein H. Drug release mechanisms of hot-melt extruded starch-based pellets. Starch - Stärke. 2012;64(5):408–19.